Incannex Healthcare Limited is a clinical-stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs. Incannex Healthcare Limited is based in MELBOURNE, Australia.
| Revenue (Most Recent Fiscal Year) | $0.09M |
| Net Income (Most Recent Fiscal Year) | $-46.88M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.69 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -54517.44% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -671.36% |
| Return on Assets (Trailing 12 Months) | -298.35% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.86 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.86 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.07 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | $-0.65 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.21 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 347.71M |
| Free Float | 293.85M |
| Market Capitalization | $136.16M |
| Average Volume (Last 20 Days) | 35.41M |
| Beta (Past 60 Months) | 7.50 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 15.49% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.43% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |